Hodgkin Lymphoma
The latest news, research, and perspectives in Hodgkin lymphoma. Both types of Hodgkin lymphoma, classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma, affect the lymphatic system and advances in diagnosis and treatment have led to high cure rates.
Advertisement
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
The primary objective of the phase II portion was to evaluate the two-year PFS rate with the treatment.
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Key advances in understanding and detecting ctDNA could usher in a future with less invasive, but more informative biopsies.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Advertisement
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
In this video interview, Dr. Mats Ehinger discusses the future of flow cytometry in lymphoma diagnostics.
Multiple regression did not define any independent predictor of response for early evaluation among the baseline parameters.
Most patients were able to avoid escBEACOPP plus radiotherapy based on PET results.
The study compared nivolumab plus AVD with brentuximab vedotin plus AVD in advanced stage classic Hodgkin lymphoma.
The study showed that nivolumab plus AVD improved PFS over brentuximab vedotin plus AVD.
BV-AVEPC showed “consistent efficacy” in pediatric patients across age groups “despite lower exposure."
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Post-AHSCT consolidation with brentuximab vedotin plus nivolumab was “highly active” in relapsed/refractory Hodgkin ...
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse.
The FDA approved brentuximab vedotin for pediatric patients with previously untreated high-risk classic Hodgkin lymphoma.
Penpulimab demonstrated a good safety profile in patients with relapsed/refractory classical Hodgkin lymphoma.
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.